The endemic treponematosis yaws remains a significant cause of morbidity in many tropical countries, despite mass treatment campaigns to eradicate it. An outbreak of yaws in Marup village on Karkar Island, Papua New Guinea in 1988 provided an opportunity to monitor the outcome of treatment with penicillin over an extended period. Thirty-nine children with clinical yaws (6% of 632 examined) were monitored clinically and serologically, for nearly two years after mass treatment of all villagers with the World Health Organization recommended dosages of benzathine penicillin. Lesions resolved within one month of treatment in all but four (10%) children, three of whom were initially successfully retreated. Before treatment, the Venereal Disease Research Laboratory (VDRL) test result was reactive in 67% of the children and treponema-specific IgM antibody test results were reactive in 41%. Within six months of treatment, of those reactive, the VDRL titer decreased significantly in 25 (96%) of 26 and IgM antibody test results became negative in 13 (81%) of 16 children. However, by the end of follow-up, 11 (28%) of the 39 children had developed clinical and/or serologic evidence of relapse. In these children, response to further treatment was slow and, in three, evidence of active infection persisted or recurred, despite repeated courses. Exogenous reinfection was unlikely in this isolated community, in which the occurrence of yaws was closely monitored after universal treatment. Treatment failure was most likely to have been due to reduced susceptibility to penicillin of Treponema pallidum subsp. pertenue.
Yaws is an endemic treponematosis caused by Treponema pallidum subsp. pertenue that causes granulomatous skin and bone lesions. A dramatic decrease in the prevalence of yaws followed the national mass penicillin treatment campaigns undertaken during the 1950s and 1960s with the support of the World Health Organization (WHO) and the United Nations Children's Fund. However, endemic foci persisted and in the last 20 years there has been a resurgence of yaws in Africa and in the western Pacific region. Today yaws remains a significant cause of morbidity in many tropical countries despite repeated mass treatment campaigns to eradicate it. In Papua New Guinea, yaws was a significant health problem prior to the nationwide mass treatment campaign that was conducted from 1953 to 1958.
On Karkar Island, Madang Province, Papua New Guinea, the mass treatment campaign in 1955 initially appeared to be successful. Karkar is a small volcanic island with a population of 30,000 comprising two geographically separate populations, the Waskia and the Takia. In 1969, 4% of the Waskia children had clinical evidence and 18% had serologic evidence of active yaws. Evidence of past infection was found in two-thirds of the Waskia compared with about onethird of the Takia. 1 Following another outbreak in 1977, 92-95% of members of both groups were treated with penicillin in 1978. During this outbreak, it was reported that although lesions were less florid, the response to treatment was slower than during earlier treatment campaigns. 2 Nevertheless, at the end of this campaign, the prevalence of active disease was less than 5% and remained low during the next decade. 2 In 1988, another outbreak of yaws occurred on Karkar Island in the isolated Takia village of Marup, with a population of 1,600. The village is away from the coast on the high slopes, and is only accessible by a steep narrow track. This study was undertaken to document the clinical and serologic response to treatment of Marup children and to identify factors that may contribute to the persistence of yaws on Karkar Island, despite the repeated mass treatment campaigns.
MATERIALS AND METHODS
In 1988, 632 children 0-15 years of age in Marup village on Karkar Island, Papua New Guinea were examined for clinical evidence of active yaws with the assistance of local Papua New Guinean health workers. Early yaws lesions consistent with those described by Hackett 3 were found in 39 (6%) children. Dark-field microscopy (DFM) and serologic tests were performed on these 39 clinical cases. All village members were then treated according to the WHO treatment schedule for the endemic treponematoses: benzathine penicillin given by intramuscular injection, 0.6 ϫ 10 6 international units (IU) for children less than 10 years of age and 1.2 ϫ10 6 IU for those 10 years of age or older. 4 Affected children were examined and blood was collected for serologic testing one month after treatment and then at three monthly intervals for 12 months. Records of reviews and of any treatment for recurring clinical or serologic evidence of yaws or other conditions over the 12-month period were kept in health record books that were collected at the end of the 12 months. Clinical reviews and serologic tests were repeated 19 and 22 months after treatment. Treatment success was defined as resolution of clinical lesions and an adequate serologic response in those patients with a reactive Venereal Disease Research Laboratory (VDRL) test result and/or reactive treponema-specific IgM test results; the VDRL test result should show a four-fold decrease in titer or seroconversion to nonreactive and the IgM test results should show seroconversion to nonreactive. Criteria for determining relapse/reinfection included new evidence of clinical yaws, a four-fold increase in VDRL test titer and/or seroconversion to reactive of the IgM test results. If a child failed to present at a review, the previous results were recorded.
The study was undertaken with the informed consent of the village residents and with the full cooperation and support of the parents whose children were included in the co- hort, and was approved by the Medical Research Advisory Committee of Papua New Guinea. There was another mass treatment campaign on Karkar Island in late 1990 using a modified WHO treatment schedule: children 0-2 and 3-5 years of age were given 0.24 ϫ 10 6 and 0.48 ϫ10 6 IU of benzathine penicillin, respectively. More than half the original cohort of 39 children was subsequently reviewed in 1995, approximately seven years after the initial examination (to be reported separately).
Collection and storage of specimens. Dark-field microscopy was performed on exudate collected directly onto glass slides from suitable lesions. Blood samples were collected by venipuncture and separated; sera were stored at Ϫ20ЊC prior to transportation by air to the Institute of Clinical Pathology and Medical Research, Westmead, Sydney, New South Wales, Australia.
Serologic tests. All sera were examined by the VDRL test (Behringwerke, Marburg, Germany) and the fluorescent treponemal antibody absorption (FTA-ABS) test (the sorbent was obtained from BioMerieux, Marcy-l'Etoile, France and the IgG conjugate was obtained from Behringwerke) using standard methods. 5 The T. pallidum hemagglutination (TPHA) test was performed according to the manufacturer's instructions (TPHA test; Japan Lyophilization Laboratory, Tokyo, Japan). Sera were tested for Treponema-specific IgM antibody by the IgM FTA-ABS test (goat antihuman IgM conjugate; Tago Immunologicals, Biosource, Camarillo, CA) and the IgM capture ELISA (IgM ELISA) (Captia Syphilis-M; Mercia Diagnostics Ltd., Shalford, United Kingdom). The cut-off value between reactive and nonreactive was set at the absorbance of the low positive control. Samples showing an absorption within 10% of the low positive control were retested. For the IgM FTA-ABS test, sera were pretreated with anti-human IgG (Gullsorb IgG inactivation reagent; Gull Laboratories, Salt Lake City, UT) according to the manufacturer's instructions; these sera then had a dilution factor of 1:10. Sera reactive in either IgM test were tested for rheumatoid factor (RF) using a latex agglutination test (RA Latex Reagent; Commonwealth Serum Laboratories, Ltd., Parkville, Victoria, Australia).
Benzathine penicillin assay. Transport and storage of the benzathine penicillin used in the treatment of the Marup villagers was according to the manufacturer's recommendations (Helm Pharmaceuticals, Munster, Germany). One ampule containing 2.4 ϫ 10 6 IU of benzathine penicillin in powder form for reconstitution, from each of three batches, was subsequently sent to the Therapeutic Goods Administration Laboratories (Woden, Australian Capital Territory, Australia) for assay. The samples were examined for fill weight, mg/g (imidazole method) and for water content (Karl Fischer trimetric method). 6 
RESULTS
All 39 children between 0 and 15 years of age had clinical evidence of early yaws. The majority (72%) of the affected children were between four and nine years of age (mean ϭ 6.4 years). There were 27 (69%) males and 12 (31%) females; the male-to-female ratio (M:F) was 2.25. The M:F varied with age from 0.9 in the 4-6-year-old age group to 5.5 in the 7-9-year-old age group.
Previous treatment with penicillin. Eight of the 39 children had been recently treated with penicillin: six had received courses of procaine penicillin within the previous three months, three for five days, and three for 1-3 days; two had received benzathine penicillin within the previous two weeks. Thus, five of the eight had received courses of penicillin that should have been adequate for cure. Their lesions appeared to be healing, but the results of DFM were reactive in all but one. These eight children were treated again at the same time as the other members of the village.
Clinical lesions. The majority of lesions were either solitary or multiple papillomata, most commonly on the lower limbs but also on face, trunk, buttocks, arm, and hand. Other lesions included papules and ulceropapillomatous lesions. Many healed lesions were noted. Dactylitis and periostitis, subsequently confirmed by radiography, were observed in one child and clinical evidence of nasal bone periostitis (goundou) was seen in another two children. There was no apparent correlation between the morphology of the clinical lesions and results of serologic tests.
Dark-field microscopy. The results of DFM of lesions were positive in 32 (91%) of 35 children tested (including seven of eight who had recently received penicillin). This procedure was not performed in four children because the lesions were unsuitable (two children) or the children were not available on the day of testing; all four had typical clinical lesions and reactive serologic test results. Of the three children with negative DFM results, two had reactive serology and all had characteristic lesions. Consequently, the clinical diagnosis was confirmed by DFM and/or serology in 38 of 39 cases.
Benzathine penicillin assay. All samples met international standards for fill weight and water content and were reported to be of satisfactory standard.
Serologic test results prior to treatment. Children were divided into three serologic groups by VDRL test result: a VDRL titre Ն 8, a VDRL titer Ͻ 8, and a nonreactive VDRL test result. The age and sex distribution of children in these groups are shown in Table 1 . Two-thirds of the subjects had a reactive VDRL test result and their mean ages increased with the higher titers. The M:F ratio was particularly high (14:1) in the group with a VDRL titer Ն 8 compared with 2.7 and 0.6 in the other groups.
The serologic test results are shown in Table 2 . Five children were reactive only in one test: four in the FTA-ABS test and one in the IgM ELISA. Another three children were nonreactive in all tests. The results of the IgM FTA-ABS test and the IgM ELISA were reactive in 10 (26%) and 11 (28%) children, respectively, but only five children were reactive in both tests. The RF latex test result was nonreactive in all sera reactive in the IgM tests.
Clinical response to treatment. There was no evidence of anaphylaxis in any of the children following the initial or subsequent treatments. In 35 children, the lesions healed within a month of treatment. The remaining four children required one or two additional doses of benzathine penicillin before the initial lesions healed. Despite this, by 22 months clinical lesions had recurred in two of these four children and in another child who had responded to the first course of penicillin (Table 3 ). These three children demonstrated serologic evidence of relapse/reinfection prior to the appearance of the lesions. In one of these, treponemes were detected by an ELISA antigen test (Visuwell Syphilis Antigen, ADI Diagnostics Inc., Rexdale, Ontario, Canada) that was under evaluation (Backhouse JL, unpublished data).
Serologic response to treatment. Table 4 shows the results of the VDRL test following treatment. Of the 26 children reactive in the VDRL test, a four-fold or greater decrease in titer or seroconversion was seen in 19 of 23 tested three months after treatment and in three who were first retested at six months. However, two children demonstrated a four-fold increase in titer at six and nine months, respectively. Two other children demonstrated a significant increase in titer between 19 and 22 months. One child not present at the 12-and 19-month follow-ups showed an eightfold increase in titer at 22 months.
The IgM test results became nonreactive after treatment in all 16 children who were initially reactive ( Table 5 ). Of 10 with reactive IgM FTA-ABS test results, four had seroconverted by one month and all were nonreactive at the three-month follow-up. Seroreversion of the IgM ELISA in 11 children with reactive results took from one to nine months; the longer times were seen mainly in the VDRL test-reactive groups.
Serologic evidence of relapse/reinfection and associated clinical lesions. Serologic evidence of relapse/reinfection was found in 11 children, including two of five who had apparently adequate courses of treatment before the study began. Five children had four-fold or greater increases in VDRL titers (Table 4 ) and nine seroconverted to a reactive IgM ELISA result ( Table 5 ). Of these nine, four had also been reactive prior to treatment. Only three children were reactive in both the VDRL test and the IgM ELISA. Among children with serologic evidence of relapse/reinfection, there were three brothers in one family and two in another.
Subsequent follow-up. At the time of the 1990 mass treatment campaign, eight months after the last review, seven of the original cohort had clinical yaws. Four of these children were among the group of 11 with previous evidence of reactivation during the 22-month follow-up period. All four had been reactive in the IgM ELISA and two had also shown a four-fold increase in VDRL titer. Over the subsequent four years, there were additional reports of recrudescence of yaws (Backhouse JL, unpublished data). In a 1995 study, 70 subjects, of whom 22 were from the original cohort of 39 children, were examined clinically. Twenty of these children from the original cohort were tested and eight had VDRL titers Ն 8, although only two had active lesions. Clinical yaws was seen in another eight children (not in the original cohort), all of whom had reactive serology, seven with VDRL titers Ն 8.
DISCUSSION
Yaws has remained a significant problem on Karkar Island, despite repeated mass treatment campaigns. In 1988, 39 (6%) of 632 children examined by experienced health workers in isolated Marup village had early yaws lesions, including eight who had recently been treated with penicillin. The lesions were sparse and relatively mild, as described previously after mass treatment campaigns. 2, 7, 8 Nevertheless, DFM examination results were positive in 91% of the cases, including five children who had received doses of penicillin within the preceding 2-12 weeks, which should have been curative. This was unexpected since spirochetes are usually not detectable by DFM in yaws lesions within 8-10 hr of treatment. 9 Even after another course of treatment, one of these children had a recurrent yaws lesions and she and two others had serologic evidence of relapse within the first 12 months of follow-up. All responded to a third course of treatment.
Serologic testing was less sensitive than DFM for confirmation of the diagnosis of active yaws. Two-thirds of the subjects had reactive VDRL test results and Treponema-specific IgM was detected in 41%. There was a poor correlation between VDRL test results with high titers (Ն 8) and a reactive IgM test result, and between IgM FTA-ABS and the IgM ELISA results. These findings in children with active yaws lesions contrast with those expected in early syphilis, in which a high-titer VDRL test result and a positive IgM test result (by either method) were found in approximately 90% of the cases. 10, 11 It has been shown that the IgM ELISA is as effective as the 19SIgM FTA-ABS test, 11 which is considered to be the gold standard for syphilis serology, but less effective than the VDRL test, in monitoring response to treatment of syphilis. 10 In this study, the response of the IgM ELISA was comparable with that of the VDRL in all but two cases, in which it took longer to become nonreactive. The IgM FTA-ABS test was the most sensitive indicator of successful treatment, whereas only the VDRL test and the IgM ELISA gave evidence of relapse/reinfection.
In a study on the efficacy of two doses of 1.2 ϫ 10 6 IU or 0.6 ϫ 10 6 IU of benzathine penicillin Grin and others reported that lesions resolved within days following treatment and at six months the clinical cure rates were 97% and 100% (mean ϭ 98%) and serologic improvement (VDRL titer) was 98% and 100% (mean ϭ 99%), respectively. 12 These investigators considered this work of a preliminary nature and that a study extending over a longer period was necessary to confirm the success rate. 12 To our knowledge, such a survey has not been documented prior to this report.
We found the clinical cure rate was 90% at one-month post-treatment and 97% at six months with four children retreated in this period for persistent lesions. Serologically, 89% of the children had an acceptable response within six months. However, within the same period, a subsequent fourfold increase in VDRL titer in one child indicated relapse/ reinfection. By 22 months, the relapse/reinfection rate, as indicated by the VDRL test, was 13%, seroconversion of the IgM ELISA was 23%, and the clinical relapse rate was 8%.
In summary, the initial clinical and serologic responses to treatment were satisfactory in more than 90% of children in this cohort. In most cases, the VDRL test titers showed a four-fold decrease within three months as in early syphilis following treatment and the IgM test results became nonreactive. 13 These results, and assays of the penicillin preparations used, would suggest that the therapeutic regimen was appropriate. Nevertheless, 28% of the children later showed clinical and/or serologic evidence of either relapse or reinfection. While reinfection cannot be entirely discounted, it would seem an unlikely explanation for so large a figure in an isolated community in which all of the inhabitants had been treated and monitored clinically and serologically at regular intervals. This high treatment failure rate contrasts with previously reported rates of 1-3% in yaws and suggests reduced susceptibility or tolerance to penicillin of some strains of T. pallidum subsp. pertenue. 4, 12 This is supported by the occurrence of clustering of treatment failures within families; of the 11 children in whom relapse occurred, two were in one family and three in another. Moreover, when this population was reviewed in 1995, the incidence of yaws had risen again to levels similar to that in 1988-1990 and eight of 20 from the original cohort again had evidence of active infection.
The reported presence of plasmid DNA in one strain of T. pallidum has led researchers to postulate that T. pallidum has the potential to develop resistance to penicillin. 14, 15 Our study suggests this has occurred in T. pallidum subsp. pertenue in some children on Karkar Island. Further investigations are underway to substantiate reduced susceptibility to penicillin by inoculation of lesion exudates collected in 1995 into rabbits and monitoring their response to penicillin therapy. The implications of this observation, if confirmed, for mass treatment programs in remaining yaws-endemic areas are potentially very serious. Furthermore, reduced responsiveness to penicillin therapy in yaws raises the possibility that it could also occur in other treponematoses, including syphilis.
